Overview - Bayer Investor Relations

Create Value for our

Shareholders

We want to create value for our shareholders through innovation, growth and high earning power.

Investor News

July 09, 2020

Not intended for U.S. and UK Media

Bayer's finerenone meets primary endpoint in Phase III FIDELIO-DKD renal outcomes study in patients with chronic kidney disease and type 2 diabetes

July 08, 2020

Bayer remains committed to Roundup™ settlement

News Overview

June 24-25, 2020

Investor Conference Calls

Agreements to Resolve Major Legacy Monsanto Litigation

Monday, April 27, 2020

Investor Conference Call

Publication of Q1 2020 Results

Financial Report

Quarterly Statement Q1 2020

Publication of our First Quarter 2020 results on April 27, 2020.

as of June 24, 2020

Bayer announces agreements to resolve major legacy Monsanto litigation

ALL IN ONE

Get all Q1 2020 materials in one package

Download all documents on our First Quarter 2020 results in one ZIP file.

Download

Coronavirus

Update on COVID-19

Tailored to your interest

Key Messages

Read Key Messages to Investors

Current Event

August 4, 2020

Half-Year Report 2020

Overview

Latest Reports and Handout

Quarterly Statement Q1 2020 Investor Handout

ANNUAL REPORT

Annual Report 2019

Publication of our Full Year 2019 results on February 27, 2020.

Environment Social Governance

Socially Responsible Investing

December 10, 2019

Investor Conference Call: Bayer 2030 Sustainable Development Objectives

Uses and Safety Record

Let's Talk About Glyphosate

Learn About The Litigation

Glyphosate Litigation Facts

February 13, 2020

Crop Science R&D Pipeline Update

August 1 - 2, 2019 // St. Louis